FDA advisors spurn GSK's Blenrep comeback dreams on safety, trial concerns

17th July 2025 Uncategorised 0

Members of the FDA’s Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side effects, proposed dosing and a lack of diversity in GSK’s trial program.

More: FDA advisors spurn GSK's Blenrep comeback dreams on safety, trial concerns
Source: fierce